BenevolentAI

Equities

BAI

LU2355630455

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam Other stock markets 11:19:25 2024-05-02 am EDT			5-day change	1st Jan Change
0.64 ^EUR	0.00%		-5.88%	-40.74%

03:30pm	Benevolentai S.A. Announces Directorate Changes	CI
Apr. 15	BenevolentAI S.A. Announces Board Resignations, Effective from May 2, 2024	CI

BenevolentAI S.A. Announces Board Resignations, Effective from May 2, 2024

April 15, 2024 at 01:00 am EDT

BenevolentAI S.A. announced that Dr. François Nader, Chair of the Board, Dr. Olivier Brandicourt, Dr. Susan Liautaud and Mr. Marcello Damiani, all Non-Executive Directors, will resign as directors of BenevolentAI effective as of the close of the Company?s AGM on 2 May 2024.

Latest news about BenevolentAI

Benevolentai S.A. Announces Directorate Changes	09:30am	CI
BenevolentAI S.A. Announces Board Resignations, Effective from May 2, 2024	Apr. 15	CI
BenevolentAI Founder Reportedly Calls for Board Revamp	Apr. 02	MT
BenevolentAI Founder Reportedly Calls for Board Revamp	Apr. 02	MT
Kenneth Mulvany Sends a Letter to Benovelent AI	Apr. 02	CI
EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises	Apr. 02	AN
BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers	Mar. 25	CI
BenevolentAI Announces Executive Changes	Mar. 20	CI
BenevolentAI S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
BenevolentAI Appoints Joerg Moeller as Executive Board Member	Jan. 24	CI
BenevolentAI Appoints Joerg Moeller as Chief Executive Officer	Jan. 24	CI
Oxford Nanopore appoints Keher to CFO as Cowper becomes COO	Jan. 22	AN
EARNINGS: Symphony bemoans "weak global demand"; Aseana sells assets	23-09-26	AN
BenevolentAI S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-21	CI
BenevolentAI S.A. Announces Executive Changes	23-09-21	CI
BenevolentAI S.A. Announces Management Changes	23-09-21	CI
Merck KGaA Enters Deal With BenevolentAI, Exscientia for AI-Based Drug Discovery	23-09-20	DJ
Merck Enlists 2 UK AI Companies to Collaborate on Drug Discoveries	23-09-20	MT
BenevolentAI Signs Strategic Collaboration with Merck	23-09-20	CI
BenevolentAI Appoints Chief Revenue Officer	23-09-18	MT
BenevolentAI Appoints Catherine Isted as Chief Financial Officer	23-09-11	CI
BenevolentAI Doses First Participants in Clinical Trial of Ben-8744; Targets Pde10, an Ai-Derived Novel Target for the Treatment of Ulcerative Colitis	23-08-31	CI
BenevolentAI Announces Retirement of Jackie Hunter as Non-Executive Director	23-06-21	CI
BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies	23-06-05	CI
BenevolentAI Announces New Preclinical Data on Ai-Generated Target Identified in Their Ongoing Collaboration with Astrazeneca	23-05-31	CI

Chart BenevolentAI

Duration

Period

More charts

Company Profile

BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery. The Company serves patients by leveraging its proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery. The Company's business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck, and advancing in-house pipelines to inflection points.

Sector

Biotechnology & Medical Research

Calendar

08:00am - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for BenevolentAI

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.5464 GBP

Average target price

1.632 GBP

Spread / Average Target

+198.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BENEVOLENTAI	-40.74%	83.35M
MODERNA, INC.	+25.64%	42.68B
IQVIA HOLDINGS INC.	-2.82%	42.4B
LONZA GROUP AG	+45.32%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+7.62%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-20.09%	18.96B
MEDPACE HOLDINGS, INC.	+29.48%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.78%	11.95B
BIO-TECHNE CORPORATION	-1.62%	11.55B

Other Biotechnology & Medical Research